First study to see if de-prescribing commonly used drug class prevents or delays dementia

(Regenstrief Institute) Regenstrief Institute investigator Noll Campbell has received a five-year $3.3 million award from NIA to conduct first cause and effect trial to determine if stopping anticholinergics results in sustained improvements in cognition. If study finds that reducing or discontinuing use of these commonly prescribed drugs among current users improves brain health without adversely impacting other medical conditions, study will have identified a way to decrease an estimated 50,000 new cases of dementia annually in US.